Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a ...

Tryptamine Therapeutics ( ($AU:TYP) ) just unveiled an announcement. Tryptamine Therapeutics Limited has announced a proposed issue of 2,000,000 ...

Tryptamine’s companion biomarker program builds on the Entropic Brain Hypothesis, pioneered by Carhart-Harris, and combines machine learning algorithms with closed-loop EEG monitoring to ...

Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a first-of-its-kind EEG-based brain entropy biomarker. Carhart-Harris, who is chair ...

Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a first-of-its-kind EEG-based brain entropy biomarker. Carhart-Harris, who is chair ...

Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a first-of-its-kind EEG-based brain entropy biomarker. Carhart-Harris, who is chair ...

Tryptamine has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating disorder trial. Special Report 2 min read August 7, 2025 - 2:47PM ...

Tryptamine Therapeutics (AU:TYP) has released an update.Jason Carroll, a director of Tryptamine Therapeutics Limited, has increased his direct interest in the company by acquiring 952,748 ordinary ...

Tryptamine has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating disorder trial. Special Report 2 min read August 7, 2025 - 3:17PM ...

Tryptamine Therapeutics Limited has announced a significant change in director Jason Carroll’s holdings, with the acquisition of 1,692,514 ordinary shares at a total value of $36,090.04.

Tryptamine has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating disorder trial. Don't miss out on the headlines from ...

Special Report: Tryptamine Therapeutics is edging closer to first patient dosing in its world-first clinical trial for binge eating disorder (BED) with TRP-8803, an intravenously infused (IV ...